Camlin fine sciences completes vinpai acquisition, boosts market presence

Camlin Fine Sciences Limited announced the completion of its preferential issue on November 30, 2025. This involved allotting 4,106,181 fully paid-up equity shares at ₹247.69 per share, totaling ₹1,01,70,59,971.89. This transaction was in consideration for the acquisition of 2,723,316 ordinary shares of Vinpai, a French company, representing a 78.68% majority stake. This move increases Camlin Fine Sciences’ paid-up equity share capital.

Vinpai, incorporated in 2011, specializes in natural ingredients for the food, cosmetics, and medical industries. The acquisition is expected to enhance Camlin Fine Sciences' product range, improve existing product quality through Vinpai's technology, and expand into the feed market, generating additional revenue. Vinpai generated a turnover of €9.157 million in 2024.

Regulatory approvals from the National Stock Exchange of India Limited and BSE Limited were received on November 18, 2025, facilitating the issuance of shares to the sellers. The preferential issue shares will rank pari-passu with existing equity shares.